Compare ImmunityBio Inc. Common Stock (IBRX) vs Lockheed Martin Corporation (LMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ImmunityBio Inc. Common Stock vs Lockheed Martin Corporation — how do they compare? ImmunityBio Inc. Common Stock trades at $9.98 (market cap $10.51B), while Lockheed Martin Corporation trades at $508.09 (market cap $117.22B). The key difference: Lockheed Martin Corporation is far larger — about 11.2× ImmunityBio Inc. Common Stock's market cap, and Lockheed Martin Corporation pays a 2.72% dividend while ImmunityBio Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold ImmunityBio Inc. Common Stock for 0 Days and Lockheed Martin Corporation for 86 Days on average.
| IBRX | LMT | |
|---|---|---|
Market Cap | $10.51B | $117.22B |
Volume | 10,445,785 | 1,101,121 |
Sector | Health | Industrials |
52-Week High | $11.55 | $676.70 |
52-Week Low | $1.98 | $439.19 |
Typical Hold Time | 0 Days | 86 Days |
Enterprise Value | $10.97B | $133.96B |
Dividend Yield | — | 2.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Lockheed Martin (LMT) trades at $499.22, down 2.14% on the day, amid a bearish technical signal and recent earnings volatility. The company reported revenue growth to $75.05B in 2025, but net income margin declined to 6.68%. Analyst consensus remains bullish with a $635.33 price target, supported by strong defense spending trends and a 23-year dividend growth streak. Recent news highlights AI integration and F-35 program developments, though fixed-price contract risks persist.
LMT offers value with a P/E of 18.41 and robust cash flow, but faces execution risks from contract missteps and debt levels near 36% of assets. Upside hinges on defense budget continuity and operational efficiency, while margin pressure and competitive threats from peers like Boeing pose challenges. The stock's current discount to analyst targets presents a potential entry point for long-term investors, balanced by near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ImmunityBio Inc. Common Stock
ImmunityBio develops immune-based therapies for cancer and infectious diseases. Its programs are designed to activate and strengthen the body’s immune response.
Read more on IBRX →About Lockheed Martin Corporation
Lockheed Martin is the largest defense contractor globally and has dominated the Western market for high-end fighter aircraft since the F-35 program was awarded in 2001. Lockheed's largest segment is aeronautics, which is dominated by the massive F-35 program. Lockheed's remaining segments are rotary and mission systems, which is mainly the Sikorsky helicopter business.
Read more on LMT →
